Lorlatinib as the First-line Treatment in China Advanced ALK+ NSCLC
Status:
Recruiting
Trial end date:
2030-08-01
Target enrollment:
Participant gender:
Summary
This phase II study is aim to investigate the efficacy, resistance mechanism, safety profile
of first-line lorlatinib in China advanced ALK+ non-small cell lung cancer (NSCLC).
Participants will receive continuous daily PO dosing of lorlatinib 100mg QD.